A Phase 1 interventional study of IBI3002 and Placebo in Healthy Participants and Asthma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Asthma with a site in Australia — 7 open to participants now, 12 under way, 5 of them phase 3. Asthma · Australia.
Among the 128 studies in Asthma with a site in Australia, this one is the 88th largest by enrollment of the 120 interventional ones that give a count, is one of 5 that started in 2024, is one of 29 in phase 1, and was the 114th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →7 of the 128 studies in Asthma with a site in Australia are open now. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
Generate Biomedicines · Sites in Australia, United States, Argentina and 16 more countries
Ages 12–80
Prana Therapies Inc · Sites in Australia, New Zealand
Ages 18–65 · Healthy volunteers
University of Melbourne · Sites in Australia
Ages 18–70 · Healthy volunteers
Windward Bio · Sites in Australia, United States, Argentina and 5 more countries
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 31 · Phase 3 49 · Phase 4 9
First in 2002; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 244 across the 120 interventional studies, 135 across the 6 observational. Of the 112 that completed or were terminated, 61 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 128 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Innovent Biologics, Inc. has 2 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
4 of the studies in Asthma with a site in Australia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT03667651Phase 3University of MelbourneThe PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants | 2027-05-31 |
| NCT06637371AmgenA Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma | 2027-04-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 128 studies in Asthma with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, randomized, double-blind, placebo-controlled, phase 1, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3002 in healthy participants and mild to moderate asthmatics. Subjects will be randomly assigned to different dosages of IBI3002 and matched placebo groups. The entire trial cycle includes a 4-week screening period, 1-day treatment period and 5-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with asthma must have:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of Placebo administered subcutaneously on Day 1
Drug: Placebo
Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6) administered subcutaneously on Day 1
Drug: IBI3002
Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1
Also known as: ICS, alone or in combination with LABA
Single dose of Placebo, administered subcutaneously on Day 1
Also known as: ICS, alone or in combination with LABA
Number of participants with AEs/SAEs
Incidence of adverse events and severe adverse events
Time frame: Baseline up to Day 36
PK parameter: Cmax
Observed maximum plasma concentration
Time frame: Baseline up to Day 36
PK parameter: tmax
Time to achieve Cmax
Time frame: Baseline up to Day 36
PK parameter: AUC
Area under the plasma concentration-time curve
Time frame: Baseline up to Day 36
Immunogenicity profiles
Frequency and titers of anti-drug antibody (ADA)
Time frame: Baseline up to Day 36
PD profile (only in asthmatics): TARC (CCL17)
Change from baseline in peripheral blood TARC (CCL17) level
Time frame: Baseline up to Day 36
PD profile (only in asthmatics): IL-13
Change from baseline in peripheral blood IL-13 level
Time frame: Baseline up to Day 36
PD profile (only in asthmatics): IgE
Change from baseline in peripheral blood Immunoglobulin
Time frame: Baseline up to Day 36
PD profile (only in asthmatics): Eosinophil
Change from baseline in peripheral blood eosinophil level
Time frame: Baseline up to Day 36
Clinical profile (only in asthmatics): FeNO
Change from baseline in Fractional exhaled Nitric Oxide
Time frame: Baseline up to Day 36
Clinical profile (only in asthmatics): Spirometry
Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (Pre-BD FEV1)
Time frame: Baseline up to Day 36
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Jul 2025, 16 months.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 16 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IBI3002
Innovent Biologics (Suzhou) Co. Ltd. →